



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|--|
| (51) International Patent Classification 6 : A61K 49/00 | | A2 | (11) International Publication Number: WO 99/55383 (43) International Publication Date: 4 November 1999 (04.11.99) |
| <p>(21) International Application Number: PCT/GB99/01247</p> <p>(22) International Filing Date: 22 April 1999 (22.04.99)</p> <p>(30) Priority Data: 9809084.8 28 April 1998 (28.04.98) GB</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/084,833 (CIP) Filed on 8 May 1998 (08.05.98)</p> <p>(71) Applicant (<i>for GB only</i>): MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(71) Applicant (<i>for all designated States except US</i>): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): CUTHBERTSON, Alan [GB/NO]; Nicomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). SOLBAKKEN, Magne [NO/NO]; Nicomed Imaging AS, Nycoveien 2, P.O.</p> | | <p>Box 4220 Torshov, N-0401 Oslo (NO). WOLFE, Henry, Raphael [US/US]; Nicomed R & D Inc., 466 Devon Park Drive, P.O. Box 6630, Wayne, PA 19087-8630 (US).</p> <p>(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> | |
| <p>(54) Title: IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS</p> <p>(57) Abstract</p> <p>Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of stabilised gas microbubble dispersions suitable for use as diagnostic and/or therapeutic agents, for example as ultrasound contrast agents.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

Improvements in or relating to diagnostic/therapeutic
agents

5

This invention relates to diagnostic and/or therapeutically active agents comprising gas microbubbles, more particularly to such agents comprising lipopeptide-stabilised gas microbubbles.

10 These agents if desired may incorporate moieties having affinity for sites and/or structures within the body so that diagnostic imaging and/or therapy of particular locations within the body may be enhanced. Of particular interest are diagnostic agents for use in 15 ultrasound imaging. Novel lipopeptides constitute a further feature of the invention.

It is well known that ultrasonic imaging comprises a potentially valuable diagnostic tool, for example in studies of the vascular system, particularly in 20 cardiography, and of tissue microvasculature. A variety of contrast agents have been proposed to enhance the acoustic images so obtained, including suspensions of solid particles, emulsified liquid droplets, gas bubbles and encapsulated gases or liquids. It is generally 25 accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate, and considerable interest has therefore been shown in the preparation of gas-containing and gas-generating 30 systems.

Initial studies involving free gas bubbles generated *in vivo* by intracardiac injection of physiologically acceptable substances have demonstrated the potential efficiency of such bubbles as contrast 35 agents in echography; such techniques are severely

- 2 -

limited in practice, however, by the short lifetime of the free bubbles. Interest has accordingly been shown in methods of stabilising gas bubbles for echocardiography and other ultrasonic studies, for 5 example using emulsifiers, oils, thickeners or sugars, or by entraining or encapsulating the gas or a precursor thereof in a variety of systems, e.g. as porous gas-containing microparticles or as encapsulated gas microbubbles.

10 There is a substantial body of prior art concerning the nature of encapsulating materials and gases which may be present within microparticles, microbubbles etc. One preferred encapsulating system uses negatively charged phospholipids as wall-forming materials to 15 stabilise gas microbubbles - see WO-A-9729783, which is hereby incorporated by reference and which contains a comprehensive review of prior art in this area. Despite a large amount of research there still remains a need for stabilised gas-filled microbubbles or microparticles 20 which can act as ultrasound contrast agents and which are both physiologically tolerable and echogenic. Many existing contrast agents, for example, are destroyed by continuous ultrasound exposure, and thus any enhancement in contrast agent stability may reduce this problem.

25 It has recently been found that certain peptides with alternating hydrophobic and hydrophilic residues may spontaneously form macroscopic peptide membranes which may be useful biomaterials for medical products, for example as vehicles for slow-diffusion drug 30 delivery, separation materials, biodegradable polymers and artificial sutures. US-A-5,670,483 describes membranes formed by the peptide EAK16 derived from the protein zuotin [see also Zhang, S in *Biopolymers* (1994) 34, 663; Zhang, S in *Biomaterials* (1995) 16, 1385; and 35 Zhang, S in *Proc. Natl. Acad. Sci* (1993) 90, 3334]. The

- 3 -

membranes are stable in aqueous solutions and are
resistant to degradation by heat, enzymatic degradation
and alkaline and acidic pH; they have also been found to
be non-cytotoxic. These peptides are soluble in aqueous
5 solutions and, according to US-A-5,670,483, require a
sequence length of at least 12 amino acid residues,
preferably more than 16 residues, in order to form
membrane structures.

Fujita, K. et al. in *Advances in Biophysics* (1997)
10 34, 127 have described supramolecular assemblies using
helical peptides. When such peptides were suspended in
an aqueous medium by a sonication method, a dispersion
of vesicles termed "peptosomes" was obtained. These
peptosomes had a similar size distribution to classical
15 liposomes, i.e. in the nanometer range; typically their
average particle size was 75 nm. Other molecular
assemblies comprising peptidic structures have been
described by Imanishi, Y. et al. in *Supramol. Sci* (1996)
13, where gramicidin A/PEG conjugates were found to form
20 peptosomes also in the nanometer size range.

It has now been found that a range of lipid-
substituted peptide derivatives, referred to herein as
lipopeptides, may be used in the formation of stabilised
gas microbubbles suitable for use as diagnostic and/or
25 therapeutic agents, for example in ultrasound
echography. Such microbubbles have been found to
exhibit good stability, for example during
ultrasonication in an imaging procedure. It has also
surprisingly been found that lipopeptides containing as
30 few as two amino acid residues may exhibit membrane
forming properties, in contrast to the findings
regarding the self-assembly peptide structures of US-A-
5,670,483. Such short lipopeptides may be prepared
relatively easily and economically and may therefore
35 possess substantial cost advantages over naturally

- 4 -

occurring, semi-synthetic or synthetic phospholipids such as phosphatidylserine.

Thus according to one aspect of the present invention there is provided a diagnostic and/or 5 therapeutically active agent, e.g. an ultrasound contrast agent, comprising encapsulated gas-filled microbubbles stabilised by membrane-forming amphiphilic lipopeptides.

Viewed from another aspect the invention provides 10 the use of an agent as hereinbefore defined as an ultrasound contrast agent.

Viewed from yet another aspect, the invention provides a method of generating enhanced images of a human or non-human animal body which comprises 15 administering to said body an agent as hereinbefore defined and generating an ultrasound, magnetic resonance, X-ray, radiographic or light image of at least a part of said body.

The macroscopic membranes may be formed from 20 individual peptide units comprising from 2 to 50 aminoacyl residues. Each peptide unit may carry one or more lipophilic hydrocarbon chains of between 5 and about 50 carbons in length.

In a preferred embodiment the number of amino acid 25 residues in the individual lipopeptide units of the invention should be the least number of residues necessary to form an effective stabilised membrane and is preferably less than 20 residues, more preferably less than 10 residues, most preferably between 2 to 8 30 residues. Clearly, keeping the number of residues to a minimum will both reduce cost and allow easier preparation of the lipopeptides of the invention.

Any amino acid residue may be used in the preparation of individual lipopeptide units according to 35 the invention, although the lipopeptides must be

- 5 -

amphiphilic. In a preferred embodiment the lipopeptides will comprise residues of amino acids selected from the readily available naturally occurring essential twenty amino acids.

5 In one embodiment a peptide unit can comprise alternating hydrophobic and hydrophilic residues, such as alanyl and diaminopropionyl, and may comprise one or more complementary sequences and/or a targeting sequence with affinity for biological receptors. In a
10 particularly preferred embodiment, charged amino acids such as lysine and glutamic acid are selected to provide side-chain functionalities comprising positively and/or negatively charged groups respectively at neutral pH. Although not wishing to be limited by theory, it is
15 envisioned that these charged groups help in the stabilisation of the outer part of the membrane by forming ion-pairs or salt bridges. The alignment of oppositely charged groups leading to membrane stability is possible only if the peptide sequences involved are
20 complementary to one another and this forms a further aspect of the invention.

The lipid component of the lipopeptides preferably comprises an alkyl, alkenyl or alkynyl chain, especially an alkyl chain. The hydrocarbon chains preferably have
25 between 5 and 25 carbons and most preferably are obtainable from readily available fatty acid derivatives. Suitable fatty acids include oleic acid, stearic acid, palmitic acid and the like; such fatty acids are well-known to the person skilled in the art.
30 The number of hydrocarbon chains per individual lipopeptide unit will vary depending on the number of amino acid residues present and will be readily determined by the person skilled in the art; typically each lipopeptide molecule will comprise one or two
35 hydrocarbon chains.

- 6 -

The peptide chains may comprise amino acid sequences that will attain self-stabilising secondary structures such as beta sheets or alpha helices. These may provide the membranes and corresponding microbubbles with advantageous performance characteristics such as stability, pharmacokinetics, biotolerability or receptor affinities. A beta sheet-forming lipopeptide, for example such as palmitoyl-(Glu-Ile-Lys-Ile)₂, will be stabilised by repeat of counterion and hydrophobicity, and may provide the surface with both ionic and hydrophobic stabilisation.

In addition to the amino acid sequences of the lipopeptides themselves having a stabilising effect, fatty acyl chains linked to amino acid residues in the lipopeptides may be selected to provide the structure with certain characteristics. Thus, for example, mixtures of cis- and trans- unsaturated acyl chains will add to the amorphous nature of the membranes, thereby allowing greater membrane flexibility, especially at higher ultrasound frequencies, e.g. providing better second harmonic signals. A similar increase in amorphous nature or reduction in crystallinity of lipid structures may be obtained by incorporating branched fatty acyl chains, including mixtures of acyl chains with differently located branching.

Alpha helices may be formed in lipopeptides for certain amino acid sequences, as is well known in the art of protein chemistry. In such sequences a number of hydrogen bonds between side chains of properly separated and selected amino acids will serve to keep the peptide chain in alpha helix structures. For example, a structure such as Lys-Lys(acyl)-Gln-Lys(diacyl)-Asn-Lys(acyl)-Gln-Leu will provide strong hydrogen bonding between the Asn and Gln side chains and provide a polar, uncharged surface for microbubbles comprising such

- 7 -

structures.

The lipopeptides described above form a further aspect of the invention and may be natural, semisynthetic or synthetic in origin, although the 5 lipopeptides of the invention are preferably produced synthetically. Thus, the invention also provides a membrane-forming amphiphilic peptide of general formula:

A-B

10


(wherein A represents a peptide comprising from 2 to 50 residues and B represents one or more hydrocarbon chains of between 5 and about 50 carbons).

In one embodiment, one or more of the peptide 15 termini or available side-chains may be coupled to a polyethylene glycol derivative in order to delay uptake by the reticulo-endothelial system. Polyethylene glycol derivatives are also considered useful in reducing opsonisation of the microbubbles by serum proteins. This 20 is considered especially relevant when targeting of the microbubbles is desirable.

In a further embodiment, multifunctional aromatic systems may be used to link the peptides and lipophilic moieties of the invention to enhance membrane stability. 25 The presence of aromatic systems may further strengthen intermolecular associations within the membrane due to $\Pi-\Pi$ stacking interactions. The aromatic group, which may be a carbocyclic or heterocyclic, mono- or polycyclic aryl group, is advantageously phenyl. It may link 30 one or more peptides along with one or more hydrophobic hydrocarbon residues. Conveniently, the peptide(s) may be linked to the aromatic system via an amide linkage; for example the N-terminus of a suitable peptide may be 35 coupled to a benzoic acid derivative. One or more hydrophobic groups such as fatty acid derivatives may be

- 8 -

linked directly to the aromatic group, for example via an amide linkage, or may be connected to the aromatic group by a suitable linker or linkers. In a preferred embodiment such lipopeptides may be represented by the
5 formula:



10

where A is an alkyl chain linked to the phenyl ring by a suitable linker, e.g. an amide group, B is either an alkyl chain linked to the phenyl ring by a suitable linker or a peptide sequence as hereinbefore described linked to the phenyl ring by a suitable linker and C is a peptide sequence as hereinbefore described linked to the phenyl ring by a suitable linker.
15

Preferably the substituents should be at the 1,3
20 and 5 positions of the phenyl ring.

A particularly preferred aromatic system is based on 3,5-diaminobenzoic acid. The diaminobenzoic acid scaffold allows for differential coupling without complicated protection strategies being employed. This
25 is due to the reduced reactivity of the second amino group following acylation of the first amino group.

Suitable linking groups for attachment of a hydrocarbon chain or peptide to the aromatic system include amino, hydroxyl, sulfhydryl, carboxyl and
30 carbonyl groups, as well as carbohydrate groups, vicinal diols, thioethers, 2-aminoalcohols, 2-aminothiols, guanidinyl groups, imidazolyl groups, phenolic groups and α -haloacetyl compounds of the type X-CH₂CO- (where X = Br, Cl or I). Other linking moieties will of course
35 be readily determined by the person skilled in the art.

- 9 -

The aromatic linked lipopeptides described above form a further aspect of the invention.

In order to form an encapsulating membrane, a homogeneous preparation of a single lipopeptide 5 component or heterogeneous mixtures of two or more complementary lipopeptide components may be used. Preferably a mixture of two complementary lipopeptide components is employed.

The membranes of the microbubbles of the invention 10 may comprise one or more mono-, di- or multi-valent metal ions and, although not wishing to be limited by theory, it is believed that the metal ions may play a role in the stabilisation of the membrane. Suitable metal ions include gadolinium (III), yttrium (III) and 15 calcium (II), but preferably the metal ion will be monovalent, e.g a sodium or potassium ion. The presence of metal ions in the membrane may also facilitate compatibility with buffering systems and may confer some complexing or chelating stability on the membrane.

20 In a further embodiment of the invention gas-filled lipopeptide microbubbles incorporating chelates which bind metal ions such as gadolinium, indium or technecium may be prepared. Lipopeptides suitable for iodination, e.g. tyrosine-containing lipopeptides, may form the 25 encapsulating membrane. In this way multi-modality imaging may be carried out.

The microbubble membrane may be a monolayer, bilayer, oligolamellar or a fibrous network of interwoven lipopeptides, for example depending on the 30 method of preparation.

Any biocompatible gas may be present in the microbubbles according to the invention, the term "gas" as used herein including any substances (including mixtures) substantially or completely in gaseous 35 (including vapour) form at the normal human body

- 10 -

temperature of 37EC. The gas may thus, for example, comprise air; nitrogen; oxygen; carbon dioxide; hydrogen; an inert gas such as helium, argon, xenon or krypton; a sulphur fluoride such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; an optionally halogenated silane such as methylsilane or dimethylsilane; a low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms), for example an alkane such as methane, ethane, a propane, a butane or a pentane, a cycloalkane such as cyclopropane, cyclobutane or cyclopentane, an alkene such as ethylene, propene, propadiene or a butene, or an alkyne such as acetylene or propyne; an ether such as dimethyl ether; a ketone; an ester; a halogenated low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms); or a mixture of any of the foregoing. Advantageously at least some of the halogen atoms in halogenated gases are fluorine atoms; thus biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethane, bromotrifluoromethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane, chlorotrifluoroethylene, fluoroethylene, ethylfluoride, 1,1-difluoroethane and perfluorocarbons, e.g. perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoro-isobutane), perfluoropentanes, perfluorohexanes and perfluoroheptanes; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g. perfluorobut-2-ene) and perfluorobutadiene; perfluoroalkynes such as perfluorobut-2-yne; and perfluorocycloalkanes such as perfluorocyclobutane, perfluoromethylcyclobutane,

- 11 -

perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentanes, perfluorocyclohexane, perfluoromethylcyclohexane and perfluorocycloheptane. Other halogenated gases include methyl chloride, fluorinated (e.g. perfluorinated) ketones such as perfluoroacetone and fluorinated (e.g. perfluorinated) ethers such as perfluorodiethyl ether. The use of perfluorinated gases, for example sulphur hexafluoride and perfluorocarbons such as perfluoropropane, perfluorobutanes and perfluoropentanes, may be particularly advantageous in view of the recognised high stability in the bloodstream of microbubbles containing such gases.

Gas microbubbles preferably have an initial average size not exceeding 10 µm (e.g. of 7 µm or less) in order to permit their free passage through the pulmonary system following administration, e.g. by intravenous injection. However, larger microbubbles may be employed where, for example, these contain a mixture of one or more relatively blood-soluble or otherwise diffusible gases such as air, oxygen, nitrogen or carbon dioxide with one or more substantially insoluble and non-diffusible gases such as perfluorocarbons. Outward diffusion of the soluble/diffusible gas content following administration will cause such microbubbles rapidly to shrink to a size which will be determined by the amount of insoluble/non-diffusible gas present and which may be selected to permit passage of the resulting microbubbles through the lung capillaries of the pulmonary system.

The lipopeptide structures discussed above may advantageously enhance membrane stability by allowing for intermolecular association through a combination hydrophobic, ion-pairing and hydrogen bonding

- 12 -

interactions. Hydrogen bonding may occur between donor and acceptor atoms on juxtaposed lipopeptide chains. Hydrophobic interactions may occur between hydrophobic moieties such as alkyl chains or a sequence of 5 hydrophobic amino acid residues, so as to form a hydrophobic inner core of the membrane.

One preferred aspect of this invention relates to the targeting of ultrasound microbubbles for disease imaging and drug delivery. Thus, viewed from another 10 aspect the invention provides a targeted diagnostic and/or therapeutically active agent, e.g. an ultrasound contrast agent, comprising (i) gas-filled microbubbles stabilised by membrane forming amphiphilic lipopeptides capable of interacting with ultrasound irradiation to 15 generate a detectable signal; (ii) one or more vector or drug molecules or a combination of both, where said vector(s) have affinity for a particular target site and/or structures within the body, e.g. for specific cells or areas of pathology; and (iii) one or more 20 linkers connecting said microbubbles and vectors, in the event that these are not directly joined.

The use of vectors to target specific areas of interest within the body is well-known in the art and their use will be routine to the skilled artisan. 25 Suitable vectors of use in the present invention include protein and peptide vectors such as antibodies, cell adhesion molecules such as L-selectin, RGD-peptides, PECAM and intergrin, vectors comprising cytokines/growth factors/peptide hormones and fragments thereof, 30 streptavidin, bacterial fibronectin-binding proteins, Fc-part of antibodies, transferrin, streptokinase/tissue plasminogen activator, plasminogen, plasmin, mast cell proteinases, elastase, lipoprotein, lipase, coagulation enzymes, extracellular superoxide dismutase, heparin 35 cofactor II, retinal survival factor, heparin-binding

- 13 -

- brain mitogen, apolipoprotein (e.g. apolipoprotein B or apolipoprotein E), adhesion-promoting proteins (e.g. purpurin), viral coat proteins (e.g. from HIV or herpes), microbial adhesins (e.g. β -amyloid precursor),
- 5 tenascin (e.g.tenascin C), vectors comprising non-peptide agonists/antagonists of cytokines/growth factors/peptide hormones/cell adhesion molecules, vectors comprising anti-angiogenic factors, vectors comprising angiogenic factors, vector molecules other
- 10 than recognized angiogenetic factors which have known affinity for receptors associated with angiogenesis, receptors/targets associated with angiogenesis, oligonucleotide vectors, modified oligonucleotide vectors, nucleoside and nucleotide vectors, receptors
- 15 comprising DNA-binding drugs, receptors comprising protease substrates, receptors comprising protease inhibitors, vectors from combinatorial libraries, carbohydrate vectors, lipid vectors and small molecule vectors such as adrenalin and betablockers.
- 20 The microbubbles of the invention may be coupled to one or more vectors either directly or through linking groups. The microbubbles may be coupled to vectors such as monoclonal antibodies which recognise specific target areas or to a secondary antibody which has a specificity
- 25 for a primary antibody which in turn has specificity for a target area. Such use of secondary antibodies is advantageous in that appropriate selection of a secondary antibody allows the preparation of "universal" microbubbles which may be used for a wide range of
- 30 applications, since the primary antibody can be tailored to particular target areas.
- Coupling of a microbubble to a desired vector may be achieved by covalent or non-covalent means for example involving interaction with one or more
- 35 functional groups located on the microbubble and/or

- 14 -

vector. Examples of chemically reactive groups which may be employed for this purpose include amino, hydroxyl, sulfhydryl, carboxyl and carbonyl groups, as well as carbohydrate groups, vicinal diols, thioethers, 5 2-aminoalcohols, 2-aminothiols, guanidinyl groups, imidazolyl groups and phenolic groups. The vector and microbubble may also be linked by a linking group; many such groups are well-known in the art. Connection of the linker to the vector and microbubble may be achieved 10 using routine synthetic chemical techniques. A comprehensive summary of known vectors and linking groups useful in targeting ultrasonic echography can be found in International Patent Publication No. WO-A-9818501, the contents of which are hereby incorporated 15 by reference.

The present invention also provides a tool for therapeutic drug delivery in combination with vector-mediated direction of the product to the desired site. By "therapeutic drug" is meant an agent having a 20 beneficial effect on a specific disease in a living human or non-human animal. Whilst combinations of drugs and ultrasound contrast agents have been proposed in, for example, WO-A-9428873 and WO-A-9507072, these products lack vectors having affinity for particular 25 sites and thereby show comparatively poor specific retention at desired sites prior to or during drug release.

Therapeutic compounds used in accordance with the present invention may be encapsulated in the interior of 30 the microbubbles or attached to or incorporated in the encapsulating walls. Thus, the therapeutic compound may be linked to a part of the wall, for example through covalent or ionic bonds, or may be physically mixed into the encapsulating material, particularly if the drug has 35 similar polarity or solubility to the membrane material,

- 15 -

so as to prevent it from leaking out of the product before its intended action in the body. Release of the drug may be initiated merely by wetting contact with blood following administration or as a consequence of 5 other internal or external influences, e.g. dissolution processes catalyzed by enzymes or the use of of ultrasound. The destruction of gas-containing microparticles using external ultrasound is a well known phenomenon in respect of ultrasound contrast agents, 10 e.g. as described in WO-A-9325241; the rate of release may be varied depending on the type of therapeutic application by using a specific amount of ultrasound energy from the transducer.

The therapeutic agent may be covalently linked to 15 the encapsulating membrane surface using a suitable linking agent. Thus, for example, one may initially prepare a lipopeptide derivative to which the drug is bonded through a biodegradable or selectively cleavable linker, followed by incorporation of the material into 20 the microbubble. Alternatively, lipidated drug molecules which do not require processing to liberate an active drug may be incorporated directly into the membrane. The active lipidated drug may, for example, be released by increasing the strength of the ultrasound 25 beam.

Exemplary drug delivery systems suitable for use in the present compositions include known therapeutic drugs or active analogues thereof containing thiol groups; these may be coupled to thiol group-containing 30 microbubbles under oxidative conditions yielding disulphide bridges. In combination with a vector or vectors such drug/vector modified microbubbles may be allowed to accumulate in the target tissue; administration of a reducing agent such as reduced 35 glutathione will then liberate drug molecules from the

- 16 -

targeted microbubbles in the vicinity of the target tissue, increasing the local concentration of the drug and enhancing its therapeutic effect. It is also possible to prepare microbubbles which may be coupled to or coated with a therapeutic drug immediately prior to use. Thus, for example, a therapeutic drug may be added to a suspension of such microbubbles in an aqueous medium and shaken in order to attach or adhere the drug to the microbubbles.

10 A comprehensive summary of the use of microbubbles in drug delivery applications can be found in the aforementioned WO-A-9818501.

The lipopeptides of the invention may, for example, be prepared by conventional peptide synthesis techniques 15 using appropriate protection. The synthesis may conveniently be carried out using an automatic peptide synthesiser, for example using the Merrifield solid phase peptide synthesis technique. Hydrocarbon chains may be coupled to the peptide at any convenient stage, 20 e.g. before a residue has been incorporated into a peptide or after the entire peptide has been synthesised, for example using standard organic chemistry procedures. It is preferred that any hydrocarbon chain carries a carboxylate functionality 25 such as an acyl chloride moiety or carboxylic acid group which may readily be coupled onto a free amino side chain or the N-terminus of the peptide. If the peptide and lipophilic components are to be linked via a aromatic system such as 3,5-diaminobenzoic acid, binding 30 to the aromatic system will be readily effected by the skilled artisan. For example, a peptide may be coupled to the carboxyl acid group of 3,5-diaminobenzoic acid by simple peptide synthesis. A fatty acid may then be coupled to one amino functional groups to yield a 1,3-disubstituted derivative; such reaction with one amino 35

- 17 -

group deactivates the other free amino functionality, so that a 1,3,5-trisubstituted compound does not result. The 1,3-disubstituted derivative may then be coupled further with a desired peptide or lipophilic group, 5 again using simple synthetic chemistry procedures, but using more severe reaction conditions.

Microbubbles according to the invention may, for example, be prepared by sonicating and warming an aqueous solution comprising the required lipopeptide(s) 10 and optionally also any metal ions and/or other desired components, while exposing the solution to an appropriate gas. Other techniques for the preparation of microbubbles, as well as appropriate isolation and purification procedures, are well known in the art.

15 The invention will now be further described with reference to the following non-limiting examples and the accompanying drawings.

In the accompanying drawings:

Figure 1 illustrates the theoretical structure of 20 part of an amphiphilic lipopeptide membrane encapsulating a gas microbubble. The membrane comprises two complementary lipopeptides comprising positively and negatively charged amino acid residues. Hydrophobic interactions are represented by the double-headed 25 arrows.

Figure 2 shows a theoretical representation of a cross-section of gas-containing monolayer membrane comprising a complementary mixture of 2x2 lipopeptides. The top view shows the hydrophobic and ion-pair 30 interactions which are believed to stabilise membrane formation.


Figure 3 illustrates the use of 3,5-diaminobenzoic acid as a peptide/lipid linker.

Example 1

Preparation of perfluropentane-containing microbubbles
 5 comprising a 1:1 w/w mixture of lipopeptides N- α -palmitoyl-N- ϵ -palmitoyl-lysanyl-lysanyl-lysanyl-lysine and N- α -palmitoyl-N- ϵ -palmitoyl-lysanyl-glutamyl-glutamyl-glutamyl-glutamic acid

10 a) Synthesis of N- α -palmitoyl-N- ϵ -palmitoyl-lysanyl-lysanyl-lysanyl-lysine

15



20

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Lys(Boc)-Wang resin on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were pre-activated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 200 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of an aliquot of crude material was carried out using a gradient of 80 to 100% B over 40 minutes (A = 0.1% TFA/water and B = 0.1% TFA/acetonitrile) at a flow rate of 9 ml/min. After lyophilization 65 mg of pure material was obtained (analytical HPLC: gradient 70-100% B where A = 0.1% TFA/water and B = 0.1% TFA/acetonitrile; column - Vydac


- 19 -

218TP54; detection at UV 214; product retention time = 12 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1136, found at 1138.

5

b) Synthesis of N- α -palmitoyl-N- ϵ -palmitoyl-lysinyl-glutamyl-glutamyl-glutamyl-glutamic acid

10



15

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Glu(OtBu)-Wang resin on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were pre-activated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 200 mg. Purification on a Sephadex G-200 column using 0.1% ammonia solution gave 30 mg of pure product - detection at UV 214. Product characterization was carried out using MALDI mass spectrometry: expected M+H at 1138, found at 1140.

30

c) Preparation of perfluoropentane-containing microbubbles comprising a 1:1 w/w mixture of the peptides from Example 1(a) and (b)

35

Stock solution 1: 1.4% propylene glycol/2.4% glycerol in water.

- 20 -

Stock solution 2: 20 mg NaCl dissolved in 10 ml water (ca. 34 mmol).

Stock Solution 3: 4 ml of stock solution 1 was mixed with 1 ml of stock solution 2.

5

The peptides from Example 1(a) and (b) (1.0 mg of each) were weighed into a clean vial and 0.6 ml of stock solution 3 was added. The mixture was firstly sonicated for 2-3 minutes then warmed to 79°C and held there for 10 several minutes. The sample was then cooled to room temperature and the head space was flushed with perfluoropentane gas. The vial was shaken in a cap mixer for 60 seconds and the resulting microbubble dispersion was transferred to a clean 5 ml vial. The 15 volume was made up to 4 ml by the addition of water. The scum was allowed to float to the top and the microbubbles were collected from below in a syringe.

d) Characterization of microbubbles

20

The semi-fractionated microbubbles of Example 1(c) were analysed by Coulter counter and for pressure stability:

| | Size distribution | % |
|----|--------------------------|----------|
| 25 | Diam. 1-10 micron | 93 |
| | Diam. 1-3 micron | 6 |
| | Diam. 3-5 micron | 29 |
| | Diam. 5-7 micron | 36 |
| | Diam. 7-10 micron | 21 |
| 30 | Diam. 10-30 micron | 7 |

Pressure stability


| | |
|-------------|--------|
| 120 mmHg | stable |
| 160 mmHg | stable |
| 35 200 mmHg | stable |

Example 2

Preparation of perfluorobutane-containing microbubbles comprising N-β-PEG₂₀₀₀-Dpr-Lys(Hds)-Lys-Lys(Hds)-Glu-OH (where Dpr = diaminopropionic acid and Hds = 2-n-hexadecylstearic acid)

a) Synthesis N-β-PEG₂₀₀₀-Dpr-Lys(Hds)-Lys-Lys(Hds)-Glu-OH

10



15

20

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Glu(OtBu)-Wang resin on a 0.2 mmol scale, using 1 mmol amino acid cartridges. Fmoc-Lys(Dde)-OH was selectively deprotected in 2% hydrazine/DMF solution prior to the coupling of 2-n-hexadecylstearic acid. All amino acids were pre-activated with HBTU. Hds and PEG₂₀₀₀ were introduced manually following pre-activation with HATU. The simultaneous removal of lipopeptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 500 mg. Purification by preparative HPLC (Vydac 218TP1022 column-diphenyl) of an aliquot of crude material was carried out using a gradient of 70 to 100% B over 40 minutes (A = water and B = methanol) at a flow

- 22 -

rate of 9 ml/minute. After lyophilization 8 mg of pure material was obtained (analytical HPLC: gradient 70-100% B where A = 0.1% TFA/water and B = 0.1% TFA/ acetonitrile; column - Vydac 218TP54; detection at UV 5 214; product retention time = 19.7 minutes). Product characterization was carried out using MALDI mass spectrometry: expected multi M+H peaks around 3600, found 3600.

10 b) Preparation of pegylated lipopeptide microbubbles

2.5 mg of lipopeptide from Example 2(a) was weighed into a clean vial and 0.5 ml of a solution of 1.4% propylene glycol/2.4% glycerol was added. The mixture was heated 15 to 60°C for 3 minutes then cooled to room temperature. The head space was flushed with perfluorobutane gas and the vial was shaken in a cap mixer for 30 seconds. The resulting microbubbles were then washed 3 times with deionised water.

20

c) Characterisation of microbubbles

The microbubbles suspension of Example 2(b) was analysed for size distribution by Coulter counter:

25

Diameter 1-3 micron - 17.0%

Diameter 3-5 micron - 32.4%

Diameter 5-7 micron - 25.3%

30

Example 3

Preparation of perfluoropentane-containing microbubbles comprising a mixture of the complementary peptides
5 Palmitoyl-Ala-Glu-Ala-Glu-Ala-Lys-Ala-Lys-Ala-Glu-Ala-
Glu-Ala-Lys-Ala-Lys-OH and Palmitoyl-Ala-Lys-Ala-Lys-
Ala-Glu-Ala-Glu-Ala-Lys-Ala-Glu-Ala-Glu-OH

a) Synthesis of Palmitoyl-Ala-Glu-Ala-Glu-Ala-Lys-Ala-
10 Lys-Ala-Glu-Ala-Glu-Ala-Lys-OH

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Lys(Boc)-Wang resin on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were pre-activated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 300 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of a 30 mg aliquot of crude material was carried out using a gradient of 70 to 100% B over 40 minutes (A = water and B = methanol) at a flow rate of 9 ml/minute. After lyophilization 13 mg of pure material was obtained (analytical HPLC: gradient 30-80% B where A = 0.1% TFA/water and B = 0.1% TFA/acetonitrile; column - Vydac 218TP54; detection at UV 214; product retention time = 12.6 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1853, found at 1858.

b) Synthesis of Palmitoyl-Ala-Lys-Ala-Lys-Ala-Glu-Ala-
Glu-Ala-Lys-Ala-Lys-Ala-Glu-Ala-Glu-OH

35 The lipopeptide was synthesised on an ABI 433A automatic

- 24 -

peptide synthesiser starting with Fmoc-Glu(OtBu)-Wang resin (Novabiochem) on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were preactivated with HBTU. Simultaneous removal
5 of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 300 mg.
Purification by preparative HPLC (Vydac 218TP1022 column) of a 30 mg aliquot of crude material was carried
10 out using a gradient of 30 to 80% B over 40 minutes (A= 0.1% TFA/water and B = 0.1% TFA/acetonitrile) at a flow rate of 9 ml/minute. After lyophilization 4 mg of pure material was obtained (Analytical HPLC: gradient 30-80% B where A = 0.1% TFA/water and B = 0.1% TFA/
15 acetonitrile; column - Vydac 218TP54; detection at UV 214; product retention time = 9.6 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1853, found at 1858.

20 c) Preparation of perfluoropentane-containing microbubbles comprising a 1:1 w/w mixture of the peptides from Example 3 (a) and (b)

Stock solution 1: 1.4% propylene glycol/2.4% glycerol
25 in water.

The peptides from Example 3(a) and (b) (0.5 mg of each) were weighed into a clean vial and 0.5 ml of stock solution 1 was added. The mixture was firstly
30 sonicated for 2-3 minutes then warmed to 79°C and held there for several minutes. The sample was cooled to room temperature and the head space was flushed with perfluoropentane gas. The vial was then shaken in a cap mixer for 120 seconds and the resulting microbubble
35 dispersion was transferred to a clean 5 ml vial. The

- 25 -

volume was made up to 4 ml by the addition of water.

The scum was allowed to float to the top and the microbubbles were collected from below in a syringe.


5 d) Characterization of microbubbles

The semi-fractionated microbubbles of Example 3(c) were analysed for size distribution by Coulter counter:

| | Size distribution | % |
|----------------------|--------------------------|----------|
| Diam. 1-10 micron | 100 | |
| Diam. 1-3 micron | 24 | |
| Diam. 3-5 micron | 51 | |
| Diam. 5-7 micron | 22 | |
| 15 Diam. 7-10 micron | 1 | |

Example 4

Preparation of perfluorobutane-containing microbubbles
 20 comprising N-[3-(2-aminoethanamido)-5-[2-(n-hecadecyl)octadecanamidol-benzoyl]-glycine



30 a) Synthesis of 3,5-di(Fmoc-amino)benzoic acid

The compound was synthesised from 3,5-diaminobenzoic acid and Fmoc-chloride using sodium bicarbonate as base in a mixture of water and a suitable organic solvent.

35 NMR analytical data were in accordance with the

- 26 -

structure.

b) Synthesis of N-[3-(2-aminoethanamido)-5-[2-(n-hecadecyl)-octadecanamido]benzoyl]glycine

5

The structure was synthesised on a 0.15 mmol scale using a manual nitrogen bubbler apparatus starting with Fmoc-Gly Wang resin and using the compound from Example 4(a), 2-n-hexadecylstearic acid and Fmoc-protected glycine.

10 Coupling was carried out using standard TBTU/HOBt/DIEA protocols. Removal of the compound from the resin was carried out using 95% TFA for 2 hours. The product was purified by preparative liquid chromatography (Vydac 218TP1022 column) using a gradient of 90 to 100% B over 15 60 minutes (A = water/0.1% TFA and B = acetonitrile/0.1% TFA) at a flow rate of 10 ml/minute. After lyophilisation a yield of 4 mg of purified material was obtained (analytical HPLC: column - Vydac 218TP54; gradient 95 to 100% B over 20 minutes (A and B as 20 above); flow rate 1.0 ml/min; retention time 24.9 minutes detected at 254 nm). Further characterisation was carried out using MALDI mass spectrometry (α -cyano-4-hydroxycinnamic acid matrix), giving m/z for [M+H]⁺ at 758 as expected.

25

c) Preparation of perfluorobutane-containing microbubbles comprising N-[3-(2-aminoethanamido)-5-[2-(n-hecadecyl)octadecanamido]-benzoyl]-glycine

30 DMF (25 μ l) was added to a suspension of the compound from Example 4(b) (1 mg) in a solution of 1.4% propylene glycol/2.4% glycerol (0.5 ml). The mixture was heated at 70°C for 2 minutes and sonicated for 2 minutes. The head space was filled with perfluorobutane and the vial 35 was shaken in a cap mixer for 45 seconds. Microscopy in

- 27 -

polarised light showed a pattern characteristic of lamellar type structure around the microbubbles.


Example 5

5

Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoylllysine

10 a) Synthesis of N^a-[3,5-di(octadecanamido)benzoyll-
lysine

15



20 The structure shown was synthesised on a 0.15 mmol scale
using a manual nitrogen bubbler apparatus starting with
Fmoc-Lys(Boc) Wang resin and using stearic acid and
Fmoc-protected 3,5-diaminobenzoic acid from Example
4(a). Coupling was carried out using standard
TBTU/HOBt/DIEA protocols. Simultaneous removal of the
25 compound from the resin and deprotection of the side
chain Boc group was carried out using 90% TFA for 3
hours. The product was purified by preparative liquid
chromatography (Vydac 218TP1022 column) using a gradient
of 90 to 100% B over 60 minutes (A = water/0.1% TFA and
30 B = 20% 2-propanol in acetonitrile/0.1% TFA) at a flow
rate of 10 ml/minute. After lyophilisation a yield of
46 mg of purified material was obtained (analytical
HPLC: column - Vydac 218TP54; gradient 95 to 100% B over
20 minutes (A = water/0.1% TFA and B = acetonitrile/0.1%
35 TFA); flow rate 1.0 ml/minute; retention time 13.2

- 28 -

minutes detected at 254 nm). Further characterisation was carried out using MALDI mass spectrometry (α -cyano-4-hydroxycinnamic acid matrix), giving m/z for [MH]⁺ at 815, expected 814.

5

b) Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)-benzoylllysine

10 A mixture of N^a-[3,5-di(octadecanamido)benzoyl]lysine (1.4 mg) and a mixture of 1.4% propylene glycol/2.4% glycerol (463 mg) was heated at 60°C for 2 minutes and then cooled. The head space was then filled with perfluorobutane and the vial was shaken in a cap mixer
 15 for 30 seconds. The resulting gas-filled microbubbles were analysed by Coulter counter and for pressure stability.

Example 6


20

Preparation of lectin-coated perfluorobutane-containing lipopeptide microbubbles for targeted ultrasound imaging

25

a) Synthesis of the thiol functionalised lipid molecule Palmitoyl-Lys(palmitoyl)-Lys-Lys-Ahx-Cys-OH (where Ahx = amino hexanoic acid)

30



35

The lipopeptide structure shown above was synthesized on

- 29 -

an ABI 433A automatic peptide synthesiser starting with Fmoc-Cys(Trt)-Wang resin on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were pre-activated using HBTU.

5 Simultaneous removal of peptide from the resin and deprotection of side-chain protecting groups was carried out in TFA containing 5% EDT and 5% water for 2 hours, giving a crude product yield of 250 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of a 40 mg
10 aliquot of crude material was carried out using a gradient of 90 to 100% B over 50 minutes (A = 0.1% TFA/water and B = MeOH) at a flow rate of 9 ml/minute. After lyophilization, 24 mg of pure material was obtained (analytical HPLC: gradient 70-100% B where B =
15 0.1% TFA/acetonitrile and A = 0.01% TFA/water; column - Vydac 218TP54; detection at UV 214 nm; product retention time = 23 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1096, found at 1099.

20
b) Preparation of perfluorobutane-containing microbubbles comprising a mixture of thiol-containing lipopeptide structure from Example 6(a) and the lipopeptide from Example 1(b)

25 2 mg of the lipopeptide from Example 1(b) and 0.5 mg of the thiol-containing lipopeptide from Example 6(a) were weighed into a clean vial and 0.6 ml of a solution containing 1.4% propylene glycol/2.4% glycerol in 0.05M NaCl was added. The mixture was warmed to 80°C for 5 minutes. The sample was cooled to room temperature and the head-space flushed with perfluoropropane gas. The vial was shaken in a cap mixer for 60 seconds and the resulting microbubbles were washed once with deionised
30 water.
35

- 30 -

c) Modification of lectin with sulpho-SMPB

To a mixture of 1 mg of fluorescein-labelled lectin (Ulex europaeus, Sigma) in PBS (0.8 ml) was added 0.1 ml
5 DMSO solution containing 1 mg Sulpho-SMPB [sulphosuccinimidyl-4-(p-maleimidophenyl)butyrate - Pierce]. The mixture was stirred for 45 minutes at room temperature then passed through a Sephadex G-200 column using PBS as eluent. The protein fraction was collected
10 and stored at 4°C prior to use.

d) Microbubble conjugation with modified lectin protein

15 To the thiol-containing lipopeptide microbubbles from Example 6(b) was added 1.5 ml of the modified lectin protein solution from Example 6(c). After adjusting the pH of the solution to 8, the conjugation reaction was allowed to proceed for 1 hour at room temperature. The
20 microbubbles were then washed extensively with water.

e) Characterisation of microbubbles

The microbubble suspension from Example 6(d) was
25 analysed by Coulter counter and for pressure stability:

Size distribution

Diam. 1-10 micron - 84%
Diam. 1-3 micron - 12.5%
30 Diam. 3-5 micron - 37%
Diam. 1-7 micron - 24%

Pressure stability

120 mmHg - stable
35 200 mmHg - stable

f) In vitro study of targeted lectin-coated perfluorobutane-containing lipopeptide microbubbles: binding to endothelial cells under flow conditions

5 The human endothelial cell line ECV 304, derived from a normal umbilical cord (ATCC CRL-1998) was cultured in 260 ml Nunc culture flasks (Chutney 153732) in RPMI 1640 medium (Bio Whittaker) to which L-Glutamine 200 mM, penicillin/streptomycin (10000 U/mL and 10000 mcg/mL)

10 and 10% fetal bovine serum (Hyclone Lot no. AFE 5183) were added. The cells were subcultured with a split ratio of 1:5 to 1:7 when reaching confluence. Cover-glasses, 22mm in diameter, were sterilised and placed on the bottom of 12 well culture plates before cells in 0.5

15 ml complete medium with serum were added on top. When the cells reached confluence the coverslips were placed in a custom made flow chamber consisting of a groove carved into a glass plate upon which the coverslip with cells was placed with the cells facing the groove,

20 thereby forming a flow channel. Microbubbles from Example 6(d) were passed from a reservoir held at 37°C through the flow chamber and back to the reservoir using a peristaltic pump. The flow rate was adjusted to simulate physiologically relevant shear rates. The flow

25 chamber was placed under a microscope and interaction between the microbubbles and cells was viewed directly. A camera mounted on the microscope was connected to a colour video printer and a monitor. A gradual accumulation of the microbubbles on the cells took

30 place, which was dependent on the flow rate. By increasing the flow rate cells started to become detached from the coverslip, with microbubbles still being bound to the cells. Control microbubbles not carrying the vector did not adhere to the endothelial

35 cells and disappeared from the cells under minimal flow

conditions.

Example 7

5 Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoyl]lysine coated with a FITC labelled lectin for targeted ultrasound imaging

10 a) Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)-benzoyl]lysine doped with a thiol-containing lipopeptide

A mixture of 1.4% propylene glycol/2.4% glycerol (1.0
15 ml) was added to a vial containing thiol-functionalised
lipopeptide (0.5 mg) from Example 6(a) and N^a-[3,5-
di(octadecanamido)benzoyl]lysine from Example 5(a) (4.5
mg). The mixture was heated at 60°C for 3 minutes and
then sonicated for 2 minutes, whereafter the head space
20 was filled with perfluorobutane and the vial was shaken
in a cap mixer for 45 seconds. The resulting
microbubbles were washed with water and large bubbles
were removed by simple flotation.

25 b) Microbubble conjugation with modified FITC-labelled lectin with Sulpho-SMPB

To the microbubble suspension from Example 7(a) was
added modified lectin solution from Example 6(c). The
30 reaction was allowed to proceed for 1 hour at room
temperature. The microbubbles were washed with
deionised water and analysed by Coulter counter (81%
between 1 and 3 µm). Presence of lectin was measured by
flow cytometry, which indicated a fluorescent population
35 of 75%.

- 33 -

c) Binding to endothelial cells


The microbubbles of Example 7(b) were analysed for endothelial cell binding according to the method of
5 Example 6(f).

Example 8

10 Preparation of charged lipopeptide microbubbles
comprising a mixture of positively and negatively
charged structures

a) Synthesis of N- α -palmitoyl-N- β -palmitoyl-L-
diaminopropionoyl-lysinyllysine amide

15



20

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide resin on a 0.2 mmol scale, using 1 mmol amino acid cartridges. All
25 amino acids and palmitic acid were pre-activated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 150 mg. Purification was performed on a
30 Sephadex G-10 gel filtration column using 1:1 methanol/water at pH 2. MALDI mass spectrometry: expected M+H at 836, found at 837. The peptide was dissolved in a 1.4% propylene glycol/2.4% glycerol standard solution at a concentration of 0.5 mg/ml prior
35 to microbubble preparation. The stock solution was


- 34 -

adjusted to pH 3 by the addition of 0.1% HCl solution.

b) Synthesis of N- α -palmitoyl-N- β -palmitoyl-L-diaminopropionyl-glutamyl-glutamic acid

5

10



The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Glu(OtBu)-Wang resin on a 0.2 mmol scale, using 1 mmol amino acid
15 cartridges. All amino acids and palmitic acid were pre-activated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 120 mg. Purification was
20 performed on a Sephadex G-10 gel filtration column using 1:1 methanol/water at pH 8. MALDI mass spectrometry: expected M+H at 839, found at 839. The peptide was dissolved in a 1.4% propylene glycol/2.4% glycerol standard solution at a concentration of 0.5 mg/ml prior
25 to microbubble preparation. The stock solution was made basic by the dropwise addition of 0.1M NaOH solution to a final pH of 9.

c) Preparation of microbubbles using lipopeptide mixtures from Example 8(a) and (b)

Different volumes of solutions from Example 8(a) and (b) were mixed together in a vial in order to yield mixtures varying in charge properties. The headspace of the vial
35 was then flushed with perfluoropentane gas and the vial

- 35 -

was shaken in a cap mixer for 2 minutes. The resulting microbubbles were then washed several times with distilled water. In a typical experiment where microbubbles with negative Zeta potential were desired, 5 0.4 ml of the lipopeptide solution from Example 8(b) and 0.2 ml of the lipopeptide solution from Example 8(a) were mixed together in a clean vial and perfluoropentane gas was added to the head space. The vial was placed on the cap mixer and shaken for 2 minutes. The 10 microbubbles were washed several times with distilled water and analysed for pressure stability, size distribution and zeta potential.

Example 9

15

Therapeutic lipopeptide microbubble formulations:
preparation of doxirubicin-loaded microbubbles

Doxirubicin was dissolved in a 1.4% propylene glycol/ 20 2.4% glycerol solution at a concentration of 0.2 mg/ml. To 0.4 ml of the stock solution of negatively charged lipopeptide from Example 8(b) in a clean vial was added 0.2 ml of the stock solution from Example 8(a) and 0.05 ml of the above doxirubicin solution. The resulting 25 solution was an orange-red colour due to the presence of doxirubicin. The head space was then flushed with perfluoropentane gas and the vial was shaken in a cap mixer for 1 minute. Following flotation of the microbubbles it was observed that the orange-red colour 30 was now to be found in the microbubble layer and that the supernatant now contained virtually no colour. The microbubbles were then washed several times with distilled water, following which they still had an orange-red appearance indicating the presence of 35 doxirubicin.

Example 10Therapeutic lipopeptide microbubble formulations:
preparation of actinomycin D-loaded microbubbles

5

The procedure of Example 9 was repeated except that actinomycin D was used in place of doxirubicin. The observed colour was yellow instead of orange-red.


10

Example 11Preparation of surface-PEGylated lipopeptide
microbubbles

15

a) Synthesis of the lipopeptide: Palmitoyl-Dpr(Palmitoyl)-Arg-Arg-Lys(PEG₂₀₀₀)-NH₂ (where Dpr = diaminopropionic acid)

20



25

The lipopeptide was partly synthesised on an ABI 433A automatic peptide synthesiser. Starting with Rink amide AM resin (0.25 mmol scale), 1 mmol each of the HBTU activated amino acid derivatives Fmoc-Lys(Dde)OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Dpr(Fmoc)-OH and palmitic acid were assembled on the polymer in the order shown above. The resin was then transferred to a nitrogen bubbler and the Dde protecting group removed by treatment with 2% hydrazine monohydrate in DMF. The PEG₂₀₀₀ moiety was then introduced by double coupling with preactivated (HATU) CH₃O-POE-NHCOCH₂CH₂COOH (mol mass:

30

35

- 37 -

2000 Dalton, Rapp Polymere). Simultaneous removal of peptide and side-chain protecting groups from the resin was carried out in TFA containing 5% phenol, 5% triisopropylsilane and 5% H₂O for 2.5 hours, yielding 27
5 mg of crude lipopeptide. Product characterisation of the crude lipopeptide was carried out using MALDI mass spectrometry: due to the heterogeneous nature of the PEG₂₀₀₀ component a complex spectrum was obtained: (M+H)⁺ expected range 2900-3200, found 2900-3200. The
10 lipopeptide was dissolved in a 1.4% propylene glycol/ 2.4% glycerol standard solution at a concentration of 0.5 mg/ml prior to microbubble preparation.

b) Microbubble preparation


15 To the lipopeptide solution from Example 8(b) (0.4 ml) in a clean vial was added 0.15 ml of the lipopeptide solution from Example 8(a) and 0.1 ml of the lipopeptide solution from Example 11(a). The head space was then
20 flushed with perfluoropentane gas and the vial was shaken on a cap mixer for 2 minutes to generate perfluoropentane-containing microbubbles. 0.4 ml of distilled water was added to the vial, which was then placed on a roller table for 3 hours. The microbubbles
25 were then washed several times with distilled water and analysed by Coulter counter.

Example 12

Preparation of charged lipopeptide microbubbles comprising a mixture of positively and negatively
5 charged structures

a) Synthesis of N- α -palmitoyl-N- β -palmitoyl-L-diaminopropionoyl-lysine

10




The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Lys(Boc)-SASRIN resin on a 0.3 mmol scale, using 1 mmol cartridges and preactivated with HBTU. Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 210 mg. MALDI mass spectrometry: expected M+H at 710, found at 709. The lipopeptide was dissolved in a 1.4% propylene glycol/2.4% glycerol standard solution at a concentration of 0.5 mg/ml prior to microbubble preparation. The stock solution was adjusted to pH 2 by the addition of 10% HCl solution.

20

b) Synthesis of N- α -palmitoyl-N- β -palmitoyl-L-diaminopropionoyl-glutamic acid

25



30

35

- 39 -

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Fmoc-Glu(OtBu)-Wang resin on a 0.3 mmol scale, using 1 mmol cartridges and HBTU activation. Simultaneous removal of peptide from 5 the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O for 2 hours, giving a crude product yield of 150 mg. MALDI mass spectrometry: expected M-H⁻ at 709, found at 709. The lipopeptide was dissolved in a 1.4 % propylene glycol/2.4% glycerol 10 standard solution at a concentration of 0.5 mg/ml prior to bubble preparation. The solution was made basic by the dropwise addition of 1M NaOH solution to a final pH of 10.

15 c) Preparation of microbubbles using lipopeptide mixtures from Example 12(a) and (b) above

To the lipopeptide solution from Example 12(b) (0.4 ml) in a clean vial was added 0.4 ml of the lipopeptide 20 solution from Example 12(a). The head space was then flushed with perfluoropentane gas and the vial was shaken in a cap mixer for 1 minute to generate gas-filled microbubbles. 0.4 ml of distilled water was added to the vial, which was then placed on a roller 25 table for 1 hour. The microbubbles were then washed several times with distilled water and analysed by Coulter counter.

Example 13


5 Synthesis of N- α -palmitoyl-N- γ -palmitoyl-L-diaminobutyroyl-lysanyl-lysanyl-PEG₃₄₀₀-lysanyl-arginyl-lysanyl-arginyl-lysanyl-arginine amide: a vector-PEG-lipid molecule suitable for incorporation into lipopeptide microbubbles

The lipopeptide was synthesised on Rink amide resin on a
10 0.1 mmol scale, using 1 mmol amino acid cartridges. The vector portion was assembled on an ABI 433 synthesiser using several rounds of Fmoc-Arg(Pmc)-OH followed by Fmoc-Lys(Boc)-OH couplings with HBTU preactivation. To introduce a PEG spacer between the vector and lipid the peptide resin was transferred to a nitrogen bubbler apparatus and Fmoc-PEG₃₄₀₀-NHS (Shearwater) coupled to the peptide resin until the Kaiser test was negative. The resin was then transferred back to the synthesiser and the assembly continued with two rounds of Fmoc-Lys(Boc)-OH, one of Di-Fmoc-diaminobutyric acid, and one of palmitic acid to introduce the lipid component.
20 Simultaneous removal of peptide from the resin and side-chain protecting groups was carried out in TFA containing 5% H₂O and 5% phenol for 2 hours. The product was purified by reverse phase preparative chromatography (column - Vydac 218TP1022; solvents A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 50-100% B over 40; flow 9 ml/minute; detection at 214 nm) Analytical HPLC of pure product: column - Vydac 218TP54; solvents A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 50-100% B over 20 minutes; flow 1.0 ml/minute; retention time 18.9 minutes detected at 214 nm). Further characterisation was carried out using MALDI mass spectrometry, expected M+H at 4500-5300, found at 4500-35 5300.

Example 14

- Synthesis of a lipopeptide with positive and negative charges suitable for microbubble preparation: Palmitoyl-
5 Dpr(Palmitoyl)-Dpr-Asp-NH₂ (where Dpr = diaminopropionic acid)


10



- The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide AM resin on a 0.25 mmol scale, using 1 mmol amino acid cartridges.
15 Palmitic acid and the Fmoc amino acid derivatives were preactivated using HBTU before coupling. Simultaneous removal of peptide and side-chain protecting groups from the resin was carried out in TFA (15 ml) containing EDT (0.2 ml) and H₂O (0.1 ml) for two hours. Purification of
20 crude material (171 mg) was achieved by recrystallisation from water/methanol (80:20, 20 ml), giving 73 mg of pure material (analytical HPLC: gradient 85-90% B where A = H₂O/0.1% TFA and B = CH₃CN/0.1% TFA; column - PLRP-S; detection at UV 214 nm; product
25 retention time 17.92 minutes). Further product characterisation was carried out using MALDI mass spectrometry: expected, M+H⁺ at 782, found at 783).

Example 15

Synthesis of a heparin sulphate-binding lipopeptide suitable for the preparation of targeted lipopeptide microbubbles: Palmitoyl-Lys(palmitoyl)-Lys-Lys-Ahx-Lys-Arg-Lys-Arg-Lys-Arg-NH₂ (where Ahx = aminohexanoic acid)




The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide resin (Novabiochem) on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were preactivated using HBTU. Firstly the heparin-binding consensus sequence was assembled using the Fmoc-Arg(Pmc)-OH and Fmoc-Lys(Boc) derivatives. This was followed by introduction of a spacer using Fmoc-aminohexanoic acid and two rounds of Fmoc-Lys(Boc)-OH. Finally the lipid component was introduced by coupling Fmoc-Lys(Fmoc)-OH followed by palmitic acid. Simultaneous removal of peptide and side-chain protecting groups from the resin was carried out in TFA containing 5% phenol, 5% triisopropylsilane and 5% H₂O for 2 hours, giving a crude product yield of 150 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of a 30 mg aliquot of crude material was carried out using a gradient of 70 to 100% B over 40 minutes (A = 0.1 % TFA/water and B = acetonitrile) at a flow rate of 9 ml/minute. After lyophilization 19 mg of pure material was obtained (analytical HPLC: gradient 70-100% B where B = acetonitrile, A = 0.01% TFA/water; column - Vydac 218TP54; detection at UV 214 nm; product retention

- 43 -

time = 11 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1845, found at 1850.

5 Example 16


Synthesis of the positively charged lipopeptide Palmitoyl-Dpr(palmitoyl)-Arg-Arg-Lys-NH₂, suitable for lipopeptide microbubble preparation (where Dpr = 10 diaminopropionic acid)



15 The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide resin (Novabiochem) on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were preactivated using HBTU. Simultaneous removal of 20 peptide and side-chain protecting groups from the resin was carried out in TFA containing 5% phenol, 5% triisopropylsilane and 5% H₂O for 2 hours, giving a crude product yield of 50 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of crude material was 25 carried out using a gradient of 90 to 100% B over 40 minutes (A = 0.1% TFA/ water and B = 0.1% TFA/ acetonitrile) at a flow rate of 9 ml/minute. After lyophilization 5 mg of pure material was obtained (analytical HPLC: gradient 80-100% B where A = 0.1% 30 TFA/water and B = 0.1% TFA/acetonitrile; column - Vydac 218TP54; detection at UV 214 nm; product retention time 15 minutes). Further product characterisation was carried out using MALDI mass spectrometry: expected M+H at 1021, found at 1022.

Example 17

Synthesis of a lipopeptide containing behenic acid
(Beh)- Beh-Asp-Ala-Asp-Ala-Dpr-Ala-Dpr-NH₂, suitable for
5 use in microbubble preparation (where Dpr =
diaminopropionic acid)



10

The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide resin (Novabiochem) on a 0.25 mmol scale, using 1 mmol amino acid cartridges. All amino acids and behenic acid were preactivated using HBTU. Simultaneous removal of peptide and side-chain protecting groups from the resin was carried out in TFA containing 5% EDT and 5% H₂O for 2 hours, giving a crude product yield of 150 mg.


Purification by preparative HPLC (Vydac 218TP1022 column) of crude material was carried out using a gradient of 70 to 100% B over 40 minutes (A = 0.1% TFA/water and B = 0.1% TFA/MeOH) at a flow rate of 9 ml/minute. After lyophilization 6 mg of pure material was obtained (analytical HPLC: gradient 70-100% B where A = 0.1% TFA/water and B = 0.1% TFA/MeOH; column - Vydac 218TP54; detection at UV 214 nm; product retention time 21 minutes). Further product characterisation was carried out using MALDI mass spectrometry: expected M+H at 955, found at 957.

Example 18

Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoyl]lysine with inclusion of a PEGylated derivative in the membrane

- a) Synthesis of a PEGylated derivative for incorporation into the microbubble membrane

10



15

The structure shown was synthesised on a 0.30 mmol scale using a manual nitrogen bubbler apparatus starting with Fmoc-Lys(Boc)-Wang resin. Amino acid, Fmoc-protected 20 3,5-diaminobenzoic acid from Example 5(a) and stearic acid were preactivated with TBTU/HOBt/DIEA. The PEGylated side chain was coupled using CH₃O-POE-NH-CO-CH₂CH₂-COOH (MW 750) from Rapp Polymere. Simultaneous removal of the compound from the resin and deprotection 25 of the side chain Boc group was carried out using 90% TFA for 2.5 hours. The product was purified by reverse phase preparative chromatography (Vydac 218TP1022 column; solvents A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 70-100% B over 60 minutes followed by 100% B for 140 minutes; flow 10 ml/minute; detection at 254 nm). A yield of 83 mg of 30 purified material was obtained (analytical HPLC: column - Vydac 218TP54; solvents: A = water/0.1% TFA and B = acetonitrile/0.1% TFA; gradient 70-100% B over 20 minutes; flow 1.0 ml/minute; retention time 17.4 minutes

- 46 -

detected at 254 nm). Further characterisation was carried out using MALDI mass spectrometry (α -cyano-4-hydroxycinnamic acid matrix), giving a distribution of $[M+H]^+$ peaks centred around m/z 1767.

5

b) Preparation of perfluorobutane-containing microbubbles comprising an 8.5:1 w/w mixture of N^a-[3,5-di(octadecanamido)benzoyl]lysine and the PEGylated derivative from Example 18(a)

10

A mixture of N^a-[3,5-di(octadecanamido)benzoyl]lysine from Example 5(a) (1.7 mg), the PEGylated derivative from Example 18(a) (0.2 mg) and a solution of 1.4% propylene glycol/2.4% glycerol (1.0 ml) was heated at 15 70°C for 2 minutes to give a homogenous suspension. The head space was filled with perfluorobutane and the vial was shaken in a cap mixer for 60 seconds. Foam was removed and the microbubbles were collected by flotation and washed three times with deionised water.

20

c) Characterisation of the microbubbles

The microbubbles from Example 18(b) were analysed by Coulter Multisizer and for pressure stability:

25

Size distribution

| | | |
|--------------------|------|---------|
| Diameter (microns) | 1-10 | - 99.8% |
| | 1-3 | - 84% |
| | 3-5 | - 13% |

30

Acoustic attenuation measurements showed the microbubbles to be stable at overpressures of 120 and 200 mmHg.

35 The presence of the PEGylated derivative from Example

- 47 -

18(a) in the membrane was confirmed as follows: an aliquot of 100 µl of the microbubble suspension was added to 200 µl of methanol and the mixture was sonicated for 20 seconds. Presence of the derivative from Example 18(a) was shown by analytical HPLC (conditions as described above). Furthermore, the mixture was analysed by MALDI mass spectrometry (α -cyano-4-hydroxycinnamic acid matrix), giving a peak at m/z 814 corresponding to $[M+H]^+$ for $N^{\alpha}-[3,5-$

10 di(octadecanamido)benzoyl]lysine and a peak distribution centred around m/z 1767 corresponding to the PEGylated derivative.


Example 19

15

Preparation of perfluorobutane-containing microbubbles comprising $N^{\alpha}-[3,5$ -di(octadecanamido)benzoyl]lysine and a lipopeptide containing captopril for therapeutic applications

20

25




30 The captopril-containing lipopeptide shown above was synthesised as described in WO-A-9818501. To a vial containing $N^{\alpha}-[3,5$ -di(octadecanamido)benzoyl]lysine (0.92 mg) and the captopril-containing lipopeptide (0.13 mg) was added a 1.4% propylene glycol/2.4% glycerol mixture (1.0 ml). The vial was heated at 60°C for 2 minutes and 35 then sonicated to give a homogeneous suspension. The

- 48 -

head space was filled with perfluorobutane and the vial was shaken in a cap mixer for 60 seconds. The resulting microbubbles were collected by flotation and washed extensively with deionised water. The microbubbles were 5 analysed by Coulter Multisizer and for pressure stability.

Example 20


10 Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoyl]lysine and a lipopeptide containing atenolol for diagnostic and therapeutic applications



The atenolol-containing lipopeptide shown above was synthesised as described in WO-A-9818501. Microbubbles 25 were formed according to the procedure described in Example 19, using 0.96 mg of N^a-[3,5-di(octadecanamido)benzoyl]lysine and 0.11 mg of the atenolol-containing lipopeptide. The microbubbles were 30 analysed by Coulter Multisizer and for pressure stability.

Example 21


Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoyl]lysine and a
 5 lipopeptide containing chlorambucil for therapeutic applications



The chlorambucil-containing lipopeptide shown above was synthesised as described in WO-A-9818501. Microbubbles were formed according to the procedure described in Example 19, using 0.97 mg of N^a-[3,5-
 20 di(octadecanamido)benzoyl]lysine and 0.13 mg of the chlorambucil-containing lipopeptide. The microbubbles were analysed by Coulter Multisizer and for pressure stability.

Example 22

Preparation of perfluorobutane-containing microbubbles comprising N^a-[3,5-di(octadecanamido)benzoyl]lysine and a
 30 lipophilic derivative of cytarabine for therapeutic applications



- 50 -

N⁴-Stearoyl-1-β-D-arabinofuranosylcytosine (structure shown above) was synthesised as described in Akiyama, M. et al. *Chem. Pharm. Bull.* 1978, 26, 981-984.


Microbubbles were formed according to the procedure 5 described in Example 19, using 0.97 mg of N^a-[3,5-di(octadecanamido)benzoyl]lysine and 0.15 mg of N⁴-stearoyl-1-β-D-arabinofuranosylcytosine. The microbubbles were analysed by Coulter Multisizer and for pressure stability.

10

Example 23

Synthesis of a lipopeptide suitable for iodination (multi-modality imaging): N-α-palmitoyl-N-e-palmitoyl-15 lysinyl-lysinyl-lysinyl-lysinyl-lysinyl-tyrosinyl-tyrosine amide

20



25 The lipopeptide was synthesised on an ABI 433A automatic peptide synthesiser starting with Rink amide resin on a 0.2 mmol scale, using 1 mmol amino acid cartridges. All amino acids and palmitic acid were preactivated with HBTU. Simultaneous removal of peptide from the resin 30 and side-chain protecting groups was carried out in TFA containing 5% H₂O and 5% EDT for 2 hours, giving a crude product yield of 300 mg. Purification by preparative HPLC (Vydac 218TP1022 column) of an aliquot of crude material was carried out using a gradient of 50 to 100% 35 B over 40 minutes (A = 0.1% TFA/water and B = 0.1%

- 51 -

TFA/acetonitrile) at a flow rate of 9 ml/minute. After lyophilization 50 mg of pure material was obtained (analytical HPLC: gradient 50-100% B where A = 0.1% TFA/water and B = 0.1% TFA/acetonitrile; column ~ Vydac 5 218TP54; detection at UV 214; product retention time = 14 minutes). Further product characterization was carried out using MALDI mass spectrometry: expected M+H at 1463, found at 1462.

Claims

1. A diagnostic and/or therapeutically active agent comprising encapsulated gas-filled microbubbles stabilised by membrane-forming amphiphilic lipopeptides.
2. A diagnostic agent as claimed in claim 1 which is an ultrasound contrast agent.
- 10 3. An agent as claimed in claim 1 or claim 2 wherein the peptide moieties of said lipopeptides each comprise less than 20 amino acid residues.
- 15 4. An agent as claimed in claim 3 wherein said peptide moieties each comprise less than 10 amino acid residues.
5. An agent as claimed in claim 4 wherein said peptide moieties each comprise from 2 to 8 amino acid residues.
- 20 6. An agent as claimed in any of the preceding claims wherein the peptide moieties of said lipopeptides consist of amino acid residues derived from naturally occurring essential amino acids.
- 25 7. An agent as claimed in any of the preceding claims wherein the peptide moieties of said lipopeptides comprise alternating hydrophilic and hydrophobic amino acid residues.
- 30 8. An agent as claimed in any of the preceding claims wherein the peptide moieties of said lipopeptides are rendered complementary by the presence of oppositely charged groups which are capable of alignment.
- 35 9. An agent as claimed in any of the preceding claims

- 53 -

wherein the lipid moieties of said lipopeptides comprise alkyl, alkenyl or alkynyl groups containing from 5 to 25 carbon atoms.

5 10. An agent as claimed in any of the preceding claims wherein the gas comprises air, nitrogen, oxygen, carbon dioxide, hydrogen, an inert gas, a sulphur fluoride, selenium hexafluoride, an optionally halogenated silane, an optionally halogenated low molecular weight hydrocarbon, an ether, a ketone, an ester or a mixture of any of the foregoing.

11. An agent as claimed in claim 10 wherein the gas comprises a perfluorocarbon or a sulphur fluoride.

15 12. An agent as claimed in claim 11 wherein the gas comprises sulphur hexafluoride, perfluoropropane, perfluorobutane or perfluoropentane.

20 13. An agent as claimed in any of the preceding claims wherein the lipopeptide has a polyethylene glycol moiety coupled thereto.

25 14. An agent as claimed in any of the preceding claims further comprising either (a) one or more vectors having affinity for a target site or structure within a human or animal body or (b) a secondary antibody having specificity for a primary antibody which in turn has specificity for such a target site or structure.

30 15. An agent as claimed in any of the preceding claims further comprising a therapeutic drug.

35 16. An agent as claimed in any of claims 1 to 13 which further includes contrast-enhancing moieties for an

- 54 -

imaging modality other than ultrasound.

17. An agent as claimed in any of claims 1 to 13 which incorporates chelates which bind metal ions.

5

18. A method of generating enhanced images of a human or non-human animal body which comprises administering to said body an agent as defined in any of the preceding claims and generating an ultrasound, magnetic resonance, 10 X-ray, radiographic or light image of at least a part of said body.

19. Membrane-forming amphiphilic lipopeptides comprising a peptide containing from 2 to 50 amino acid 15 residues and one or more hydrocarbon chains each containing from 5 to 50 carbon atoms.

20. Membrane-forming amphiphilic lipopeptides comprising an aromatic ring having at least one peptide 20 moiety containing from 2 to 50 amino acid residues and at least one hydrocarbon chain containing from 5 to 50 carbon atoms coupled or linked thereto.

21. Lipopeptides as claimed in claim 20 wherein said 25 aromatic ring is a 1,3,5-trisubstituted phenyl ring.

22. The lipopeptides disclosed herein in the Examples.




Figure 1




Figure 2




Figure 3



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|--|
| (51) International Patent Classification 6 : A61K 49/00, 41/00, 49/04, 51/12 | | A3 | (11) International Publication Number: WO 99/55383 (43) International Publication Date: 4 November 1999 (04.11.99) |
| <p>(21) International Application Number: PCT/GB99/01247</p> <p>(22) International Filing Date: 22 April 1999 (22.04.99)</p> <p>(30) Priority Data: 9809084.8 28 April 1998 (28.04.98) GB</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/084,833 (CIP) Filed on 8 May 1998 (08.05.98)</p> <p>(71) Applicant (for GB only): MARSDEN, John, Christopher [GB/GB]; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(71) Applicant (for all designated States except US): NYCOMED IMAGING AS [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CUTHBERTSON, Alan [GB/NO]; Nicomed Imaging AS, Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo (NO). SOLBAKKEN, Magne [NO/NO]; Nicomed Imaging AS, Nycoveien 2, P.O.</p> | | <p>Box 4220 Torshov, N-0401 Oslo (NO). WOLFE, Henry, Raphael [US/US]; Nicomed R & D Inc., 466 Devon Park Drive, P.O. Box 6630, Wayne, PA 19087-8630 (US).</p> <p>(74) Agents: MARSDEN, John, Christopher et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).</p> <p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 6 July 2000 (06.07.00)</p> | |

(54) Title: IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS

(57) Abstract

Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of stabilised gas microbubble dispersions suitable for use as diagnostic and/or therapeutic agents, for example as ultrasound contrast agents.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 99/01247

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K49/00 A61K41/00 A61K49/04 A61K51/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| P,X | WO 98 18495 A (MARDSEN JOHN CHRISTOPHER ;GODAL ASLAK (NO); HOEGSET ANDERS (NO); K) 7 May 1998 see examples 11,12,14,18,1 --- | 1-13,18 |
| P,X | WO 98 18498 A (MARDSEN JOHN CHRISTOPHER ;GODAL ASLAK (NO); HOEGSET ANDERS (NO); K) 7 May 1998 see examples 12-23,30 --- | 1-13,18 |
| P,X | WO 98 18497 A (COCKBAIN JULIAN ;KLAVENESS JO (NO); NAEVESTAD ANNE (NO); SOLBAKKEN) 7 May 1998 see example 5 --- | 1-13,18 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 November 1999

Date of mailing of the international search report

10.03.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

DULLAART A.W.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01247

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| P,X | CAMINATI G ET AL: "Lipoproteptides of myelin basic protein in mono- and multilayers" THIN SOLID FILMS, vol. 327-329, 31 August 1998, page 37-41 XP004151893 see paragraph CONCLUSI; example 5 --- | 1-13,18 |
| X | WO 98 05364 A (MARDEN JOHN CHRISTOPHER ;BRAENDEN JORUNN (NO); DUGSTAD HARALD (NO) 12 February 1998 see abstract; example 5 see page 5, line 6 - line 33; example 5 see page 13, line 19 - line 28; example 5 see page 13, line 19 - line 28; example 2 see page 13, line 19; claims; example 2 --- | 1-13,18 |
| Y | ONO S ET AL: "INTERACTION OF AMPHIPATHIC MODEL LIPOPEPTIDES WITH PHOSPHOLIPID BILAYERS" JOURNAL OF CHROMATOGRAPHY, vol. 597, no. 1/02, 24 April 1992, pages 293-297, XP000676280 see abstract; claims; example 2 paragraph RESULTS AND DISCUSSION see abstract; claims; example 2 --- | 1-13,18 |
| X | RAZAFINDRALAMBO H ET AL: "FOAMING PROPERTIES OF SURFACTIN, A LIPOPEPTIDE BIOSURFACTANT FROM BACILLUS SUBTILIS" JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY, vol. 73, no. 1, 1 January 1996, pages 149-151, XP002058919 paragraph RESULTS AND DISCUSSION see abstract; claims; example 2 --- | 1-13,18 |
| Y | EPAND R M: "BIOPHYSICAL STUDIES OF LIPOPEPTIDE-MEMBRANE INTERACTIONS" BIOPOLYMERS, vol. 43, no. 1, 1 January 1997, pages 15-24, XP000677643 see page 15 - page 16; claims; example 2 see page 21; claims; example 2 see page 22 - page 23; claims; example 2 --- | 1-13,18 |
| Y | WO 97 40858 A (IMARX PHARMACEUTICAL CORP) 6 November 1997 see page 22 - page 23; claims; examples --- | 1-13,18 |
| Y | US 5 580 575 A (RAMASWAMI VARADARAJAN ET AL) 3 December 1996 see page 22 - page 23; claims; example 2 --- | 1-13,18 |
| 9 | US 5 228 446 A (UNGER EVAN C) 20 July 1993 see page 22 - page 23; claims; examples --- | 1-13,18 |
| 1 | -/- | |

INTERNATIONAL SEARCH REPORT

| |
|--|
| Int'l. Application No PCT/GB 99/01247 |
|--|

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | <p>MALETINSKA, LENKA ET AL: "Angiotensin analogues palmitoylated in positions 1 and 4" J.MED.CHEM., 1997, VOL. 43, NO. 20, PAGE(S) 3271-3279, US, XP002116343 see page 22 - page 23; claims; examples; tables 1-3 see page 22 - page 23; claims; figures 1,2,4; tables 1-3 see paragraph CONCLUSI; claims; figures 1,2,4; tables 1-3 ---</p> <p>MALETINSKA, LENKA ET AL: "168. Lipid masking and reactivation of angiotensin analogues" HELV.CHIM.ACTA, 1996, VOL. 79, NO. 7, PAGE(S) 2023-2034, CH, XP002116344 see abstract; claims; figures 1,2,4; tables 1-3 see abstract; claims; figures 1,2,4; tables 1,2 paragraph Structure-Activity Relationship see abstract; claims; figures 1,2,4; tables 1,2 -----</p> | 1-13,18 |
| Y | | 1-13,18 |

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: **18**
because they relate to subject matter not required to be searched by this Authority, namely:
See additional sheet FURTHER INFORMATION SHEET PCT/ISA/210

2. Claims Nos.: **1-13, 18 in part**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See additional sheet FURTHER INFORMATION SHEET PCT/ISA/210

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims: **1, 3-13 and 18 in part, 2**
2. Claims: **1 and 3-18 in part**
3. Claims: **1 and 3-18 in part**
4. Claims: **1 and 3-18 in part**
5. Claims: **1, 3-16 and 18 in part**
6. Claims: **1, 3-14 and 18 in part, 15**
7. Claims: **19-22**

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1, 3-13 and 18 in part, 2

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 3.

Although claim 18 is directed to a diagnostic method practised on the human/animal body, a search has been carried out, based on the alleged effects of the compound/composition.

Further defect(s) under Article 17(2)(a):

Continuation of Box 3.

Claims Nos.: 1-13, 18 in part

Present claims 1-13 and 18 relate to a composition defined (*inter alia*) by reference to the expression "stabilised by membrane-forming amphiphilic lipopeptides".

The use of the parameter "membrane-forming" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is impossible to compare the parameters the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible. Since the very nature of lipopeptides (containing a lipidic = lipophilic part, and a peptide part which is generally water-soluble) generally renders them amphiphilic, only the term "membrane-forming" was disregarded during search.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1, 3-13 and 18 in part, and 2

An ultrasound contrast agent containing stabilised microbubbles as claimed, and the method of generating enhanced ultrasound images using this agent.

2. Claims: 1 and 3-18 in part

A magnetic resonance contrast agent containing stabilised microbubbles as claimed, and the method of generating enhanced magnetic resonance images using this agent.

3. Claims: 1 and 3-18 in part

An X-ray contrast agent containing stabilised microbubbles as claimed, and the method of generating enhanced X-ray images using this agent.

4. Claims: 1 and 3-18 in part

A radiographic contrast agent containing stabilised microbubbles as claimed, and the method of generating enhanced radiographic images using this agent.

5. Claims: 1, 3-16 and 18 in part

A contrast agent for light imaging techniques, containing stabilised microbubbles as claimed, and the method of generating enhanced light images using this agent.

6. Claims: 1, 3-14 and 18 in part, and 15

A therapeutic agent containing stabilised microbubbles as claimed.

7. Claims: 19-22

Membrane-forming amphiphilic lipopeptides as claimed.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No

PCT/GB 99/01247

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|--|---|------------------|--|--|
| WO 9818495 | A | 07-05-1998 | AU 4786797 A AU 4786897 A AU 4786997 A EP 0971747 A EP 0946202 A WO 9818496 A WO 9818497 A AU 4786697 A AU 4787097 A BR 9712683 A CN 1234742 A CZ 9901494 A EP 0973552 A EP 0963209 A WO 9818501 A WO 9818498 A NO 991889 A AU 4718297 A WO 9818500 A NO 991890 A AU 7068798 A EP 0977600 A WO 9847541 A | 22-05-1998 22-05-1998 22-05-1998 19-01-2000 06-10-1999 07-05-1998 07-05-1998 22-05-1998 22-05-1998 19-10-1999 10-11-1999 15-09-1999 26-01-2000 15-12-1999 07-05-1998 07-05-1998 28-06-1999 22-05-1998 07-05-1998 28-06-1999 13-11-1998 09-02-2000 29-10-1998 |
| WO 9818498 | A | 07-05-1998 | AU 4786897 A AU 4786997 A AU 4787097 A EP 0971747 A EP 0946202 A EP 0963209 A WO 9818496 A WO 9818497 A AU 4786697 A AU 4786797 A BR 9712683 A CN 1234742 A CZ 9901494 A EP 0973552 A WO 9818501 A WO 9818495 A NO 991889 A AU 4718297 A WO 9818500 A NO 991890 A AU 7068798 A EP 0977600 A WO 9847541 A | 22-05-1998 22-05-1998 22-05-1998 19-01-2000 06-10-1999 15-12-1999 07-05-1998 07-05-1998 22-05-1998 22-05-1998 19-10-1999 10-11-1999 15-09-1999 26-01-2000 07-05-1998 07-05-1998 28-06-1999 22-05-1998 07-05-1998 28-06-1999 13-11-1998 09-02-2000 29-10-1998 |
| WO 9818497 | A | 07-05-1998 | AU 4786697 A AU 4786897 A AU 4786997 A BR 9712683 A CN 1234742 A CZ 9901494 A EP 0973552 A EP 0971747 A EP 0946202 A WO 9818501 A | 22-05-1998 22-05-1998 22-05-1998 19-10-1999 10-11-1999 15-09-1999 26-01-2000 19-01-2000 06-10-1999 07-05-1998 |

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/GB 99/01247

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|---|--|
| WO 9818497 A | | WO 9818496 A NO 991889 A AU 4786797 A AU 4787097 A EP 0963209 A WO 9818495 A WO 9818498 A AU 4718297 A WO 9818500 A NO 991890 A | 07-05-1998 28-06-1999 22-05-1998 22-05-1998 15-12-1999 07-05-1998 07-05-1998 22-05-1998 07-05-1998 28-06-1999 |
| WO 9805364 A | 12-02-1998 | AU 3780497 A CN 1227502 A CZ 9900289 A EP 0918546 A NO 990276 A NZ 334365 A | 25-02-1998 01-09-1999 14-07-1999 02-06-1999 22-01-1999 28-10-1999 |
| WO 9740858 A | 06-11-1997 | US 5776429 A AU 2451097 A CN 1216925 A EP 0923383 A | 07-07-1998 19-11-1997 19-05-1999 23-06-1999 |
| US 5580575 A | 03-12-1996 | US 5228446 A US 5088499 A AU 696056 B AU 6953794 A AU 684088 B AU 7094894 A AU 8840698 A CA 2164843 A CA 2164846 A CN 1125393 A CN 1125394 A EP 0802788 A EP 0707471 A JP 9501410 T JP 8511523 T WO 9428873 A WO 9428874 A US 5542935 A US 5773024 A US 5733572 A US 5922304 A US 5705187 A US 5770222 A US 5656211 A AU 667672 B AU 2023892 A CA 2110490 A EP 0660714 A JP 6508617 T US 5469854 A WO 9222298 A US 5585112 A US 5715824 A US 5853752 A US 5935553 A | 20-07-1993 18-02-1992 27-08-1998 03-01-1995 04-12-1997 03-01-1995 04-02-1999 22-12-1994 22-12-1994 26-06-1996 26-06-1996 29-10-1997 24-04-1996 10-02-1997 03-12-1996 22-12-1994 22-12-1994 06-08-1996 30-06-1998 31-03-1998 13-07-1999 06-01-1998 23-06-1998 12-08-1997 04-04-1996 12-01-1993 23-12-1992 05-07-1995 29-09-1994 28-11-1995 23-12-1992 17-12-1996 10-02-1998 29-12-1998 10-08-1999 |

INTERNATIONAL SEARCH REPORT
Information on patent family members

| | |
|--------|---------------------|
| Inte | rial Application No |
| PCT/GB | 99/01247 |

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| US 5580575 A | | AU 667471 B AU 2002092 A CA 2110491 A EP 0616508 A JP 6508364 T US 5305757 A US 5348016 A WO 9222247 A US 5769080 A AT 180170 T CA 2069759 A DE 69033118 D EP 0511273 A EP 0707846 A ES 2131051 T | 28-03-1996 12-01-1993 23-12-1992 28-09-1994 22-09-1994 26-04-1994 20-09-1994 23-12-1992 23-06-1998 15-06-1999 23-06-1991 24-06-1999 04-11-1992 24-04-1996 16-07-1999 |
| US 5228446 A | 20-07-1993 | US 5088499 A AU 667471 B AU 2002092 A CA 2110491 A EP 0616508 A JP 6508364 T US 5305757 A US 5469854 A US 5580575 A US 5348016 A WO 9222247 A US 5585112 A US 5542935 A US 5769080 A US 5773024 A US 5733572 A US 5922304 A US 5705187 A US 5715824 A US 5770222 A US 5656211 A US 5853752 A US 5935553 A AT 180170 T CA 2069759 A DE 69033118 D EP 0511273 A EP 0707846 A ES 2131051 T GR 3030481 T JP 5502675 T US 5334381 A WO 9109629 A US 5456901 A US 5571497 A US 5776429 A US 6001335 A US 5209720 A US 5123414 A US 5230882 A US 5985246 A US 5352435 A | 18-02-1992 28-03-1996 12-01-1993 23-12-1992 28-09-1994 22-09-1994 26-04-1994 28-11-1995 03-12-1996 20-09-1994 23-12-1992 17-12-1996 06-08-1996 23-06-1998 30-06-1998 31-03-1998 13-07-1999 06-01-1998 10-02-1998 23-06-1998 12-08-1997 29-12-1998 10-08-1999 15-06-1999 23-06-1991 24-06-1999 04-11-1992 24-04-1996 16-07-1999 29-10-1999 13-05-1993 02-08-1994 11-07-1991 10-10-1995 05-11-1992 07-07-1998 14-12-1999 11-05-1993 23-06-1992 27-07-1993 16-11-1999 04-10-1994 |